CRNX vs CRSP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRNX Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crinetics Pharmaceuticals, Inc. (CRNX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, CRNX trades at N/M Forward P/E with -527.4% operating margin (+2336.3% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, CRNX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRNX Revenue | CRSP Revenue | CRNX Op. Margin | CRSP Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $0M | -1182.5% | -5087.8% | CRNX |
| FY2019 | $0M | $290M | -4512.3% | 16.1% | CRSP |
| FY2020 | $0M | $0M | -105567.6% | -49295.5% | CRSP |
| FY2021 | N/A | $910M | N/A | 40.8% | CRSP |
| FY2022 | N/A | $0M | N/A | -56190.4% | CRSP |
| FY2023 | $0M | $370M | -5547.2% | -60.0% | CRSP |
| FY2024 | $0M | $40M | -32613.5% | -1250.4% | CRSP |
| FY2025 | $10M | $0M | -6714.8% | -18933.6% | CRNX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRNX | CRSP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $9.0B | $4.1B | Larger Scale | CRNX |
| Trailing P/E Ratio Valuation | N/M | 23.4x | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | N/M | 23.4x | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +2336.3% | +1325.1% | Higher Growth | CRNX |
| Operating Margin (TTM) Profitability | -527.4% | -2058.6% | Higher Margin | CRNX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -42.4% | -25.6% | Higher ROE | CRSP |
| 52-Week Range Position Momentum | 100% ($30โ$85) | 1% ($40โ$63) | Stronger Trend | CRNX |
| Beta / 30D Volatility Risk Regime | 0.29ฮฒ ยท 2% Vol | 1.85ฮฒ ยท 60% Vol | Lower Realized Risk | CRNX |
| Unified Institutional Score Composite Signal | 46.8 / 100 (HOLD) | 44.7 / 100 (HOLD) | Higher Composite | CRNX |